Safety Reading Notes

Read safety context beside the research guide.

The PEA source set includes safety-context rows around PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms. Public reading should keep these rows beside the benefit-oriented buckets, because product identity, dose, route, population, impairment, interactions, and adverse-event context can change what a study means. PMID 35176443

Mechanistic research summary: insufficient (7), mechanistic or pharmacological (6)

PubMed For Dummies Article

PEA Evidence Review: the long-form source walk-through

Quick read
  • PEA currently has 14 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 35176443
  • The evidence classes most visible in the row language are mechanistic or pharmacological (7), and insufficient (7). PMID 39714723
  • The study-design language most visible in the row language is Narrative or expert review (6), Animal study (5), Cellular or in vitro study (1), and other mapped categories (2). PMID 15963531
  • The repeated topics are PEA biology, receptor or target pharmacology, inflammation, pain-related mech... (13), and Cannabinoids and immune modulation research outcomes (1), which tells the reader where to start opening PubMed and DOI links. PMID 40563990

Start with the research question

PEA is built from 14 source-backed evidence row(s) and 13 research source(s). The current evidence classes read as mechanistic or pharmacological (7), and insufficient (7), and the study-design language most often reads as Narrative or expert review (6), Animal study (5), Cellular or in vitro study (1), and other mapped categories (2). PMID 35176443

The row-level question is not simply whether PEA is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are PEA biology, receptor or target pharmacology, inflammation, pain-related mech... (13), and Cannabinoids and immune modulation research outcomes (1). PMID 35176443

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 41709243

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 28215162

Mechanistic evidence 7 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 10785541

Limits and uncertainty 7 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 25463999

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 33919499

Where this page has the most source density

The largest bucket surfaced for this page is PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is Cannabinoids and immune modulation, which gives readers another way to see what the literature repeatedly circles. PMID 35176443

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 35176443

Bucket chapters: what the literature is circling

PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms

13 research sources 13 rows (1106-1118) Mechanistic research summary: insufficient (7), mechanistic or pharmacological (6)

PEA appears in rows studying PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms. It currently draws from 13 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 35176443

Read this bucket as safety context first. It belongs beside any benefit-oriented rows because risk, route, dose, product quality, co-exposures, and population can change what a source means. PMID 35176443

  • Evidence row 1106

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or pati... PMID 35176443

  • Evidence row 1118

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or pati... PMID 28336953

Cannabinoids and immune modulation

1 research source 270 Mechanistic research summary: mechanistic or pharmacological (1)

PEA appears in rows studying Cannabinoids and immune modulation. It currently draws from 1 research source(s), so the population, dose, route, and endpoint should be checked before reading across contexts. PMID 35176443

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 35176443

  • Evidence row 270

    PEA studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measur... PMID 35176443

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (7 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 35176443

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 35176443

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 24602801
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 22697514
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 27720681

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 35176443

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 35176443

Source-reading checklist for PEA

  1. Open the linked PubMed or DOI record. PMID 28336953
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 35176443
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 39714723
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 15963531
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 40563990

Source Notes

PEA source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 270

    PEA studied for Cannabinoids and immune modulation research outcomes; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: Cannabinoids and immune modulation research outcomes). PMID 35176443

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice.
  2. Evidence row 1106

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 35176443

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Palmitoylethanolamide dampens neuroinflammation and anxiety-like behavior in obese mice.
  3. Evidence row 1107

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient (population or model: Cellular or in vitro model mentioned; study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 39714723

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Mechanisms and clinical applications of palmitoylethanolamide (PEA) in the treatment of neuropathic pain.
  4. Evidence row 1108

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient (study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 15963531

    Evidence class: insufficient; Study design: Narrative or expert review. Source: The search for the palmitoylethanolamide receptor.
  5. Evidence row 1109

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Cellular or in vitro model mentioned; study design: Cellular or in vitro study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 40563990

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation.
  6. Evidence row 1110

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Human clinical study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 41709243

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Probiotics and palmitoylethanolamide (PEA) for osteoarthritic pain: individual effects in a multiple baseline design study.
  7. Evidence row 1111

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 28215162

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases.
  8. Evidence row 1112

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 10785541

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabimimetic fatty acid derivatives in cancer and inflammation.
  9. Evidence row 1113

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 25463999

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Protective effect of palmitoylethanolamide in a rat model of cystitis.
  10. Evidence row 1114

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Systematic review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 33919499

    Evidence class: insufficient; Study design: Systematic review. Source: Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence.
  11. Evidence row 1115

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 24602801

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD).
  12. Evidence row 1116

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: insufficient (population or model: Animal model mentioned; study design: Narrative or expert review; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 22697514

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma.
  13. Evidence row 1117

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 27720681

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis.
  14. Evidence row 1118

    PEA studied for PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: PEA biology, receptor or target pharmacology, inflammation, pain-related mechanisms, or safety-relevant mechanisms). PMID 28336953

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor.